SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

14 Feb 2026 Evaluate
The revenue for the December 2025 quarter is pegged at Rs. 24912.70 millions, about 8.94% up against Rs. 22868.30 millions recorded during the year-ago period.The Net proft of the company remain more or less same to Rs. 6221.40  millions from Rs. 6762.30 millions ,decline by -8.00%.The company reported a degrowth in operating Profit to 8207.40 millions from 8270.10 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 24912.70 22868.30 8.94 74054.70 67685.10 9.41 88134.40 79638.50 10.67
Other Income 1315.30 1691.80 -22.25 3494.80 3954.70 -11.63 5070.60 3059.90 65.71
PBIDT 8207.40 8270.10 -0.76 24298.50 22548.60 7.76 26632.60 19771.70 34.70
Interest 155.10 210.00 -26.14 410.50 592.00 -30.66 761.10 800.70 -4.95
PBDT 7670.60 8060.10 -4.83 23649.20 21956.60 7.71 25871.50 18332.70 41.12
Depreciation 609.10 676.10 -9.91 1783.90 1919.70 -7.07 2836.10 2391.40 18.60
PBT 7061.50 7384.00 -4.37 21865.30 20036.90 9.13 23035.40 15941.30 44.50
TAX 840.10 621.70 35.13 2184.70 1398.70 56.20 2138.20 336.20 535.99
Deferred Tax -403.80 -577.10 -30.03 -1388.20 -1735.10 -19.99 -1363.10 -1994.00 -31.64
PAT 6221.40 6762.30 -8.00 19680.60 18638.20 5.59 20897.20 15605.10 33.91
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 32.94 36.16 -8.90 32.81 33.31 -1.51 30.22 24.83 21.72

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×